A new article in Headaches describes how Migraine and Autonomic Cephalgias can treat Migraine and Autonomic Cephalgias.!

Spenopalatine Ganglion Blocks and Neuromuscular Dentistry alone or combined can reduce and/or Eliminate the Nociception or painful impulses into the Trigemino-vascular System.

Dr Shapira utilizes the DNO®: Diagnostic Neuromuscular Orthotic and Ultra-low Frequency TENS to Relax the Masticatory muscles where somatic nociception enters the trigeminal nerve along with nociceptive input from the TMJoint and sinuses and nasal cavity.

Combining these treatments with resetting of the Autonomic Nervous System of the head utilizing Sphenopalatine Ganglion Blocks can offer both fast relief and prophylaxis for migraines and Autonomic Cephalgias including Cluster Headaches.

Many medications are used to block nociception and resultant headaches but NONE have ever been shown to be more effective than Neuromuscular Orthotics combined with Sphenopalatine Ganglion Blocks! Drug companies avoid comparisons because of the huge return on investments in the pharmaceutical industry.

Self-Administration of SPG Blocks is an essential element in controlling and eliminating a large number of headaches and migraines.

SASPGB or Self-Administration of SPG Blocks puts controlin the hands of patients!

The Sphenopalatine Ganglion is the largest Parasympathetic Ganglion of the head and supplies alll of the Afferent and Efferent Parasympathetic innervation to it's structures. It is VERY IMPORTANT to understand that the Sympathetic Input to the system comes from the Stellate Ganglion and post-gangliotic fibers travel up the sSmpathetic Cervical Chain to the Superior Cervical Ganglion and into the Sphenopalatine Ganglion.

The Stellate Ganglion Block is sometimes caalled the "GOG Block" Studies at the Veteran's Admministration (VA) have found that patients receiving Stellate Ganglion Blocks for Chronic Regional Pain Syndrome (or Reflex Sympathetic Dystrophy) are sometimes "cured" of PTSD with a single shot!

The Sphenopalatine Ganglion Block was first utilized in 1908 by Greenfield Sluder to treat Sluder's Neuralgia which is now thought to be Cluster Headaches or Combination of Autonomic Cephalgia and TMD particularly the Myofascial Pain and Dysfunction. In 1929 Hyram Byrd and his brother published a study on 10,000 SPG Blocks in 2000 patients for a wide rannger of disorders with great success and NO NEGATIVE SIDE EFFECTS.

Dr Sluder went on to become Chair of OTOLARYNGOLOGY and Washington University School of Medicine and wrote several books on the Sphenopalatine Ganglion Blocks effects.

1. Concerning Some Headaches and eye Disorders of Nasal Origin

2. The Syndrome of Sphenopalatine-Ganglion Neurosis.

3. Nasal Neurology: Headaches and Eye Disorders

The publication of the Book : MIRACLES ON PARK AVENUE" SAVED THE AMAZING WORK OF GREENFIELD

SLUDER FORM BEING LOST IN THE BIN OF FORGOTTEN MEDICINE!

IT TOLD THE STORY OF AND OCTOGENERIAN ENT IN NEW YORK CITY WHOSE ENTIRE PRACTICE WAS TREATMENT OF A WIDE VARIETY IF DISORDERS UTILIZING ONLY SPG BLOCKS.

DR SHAPIRA IS KNOW FOR TREATING DIFFICULT PATIENTS WITH SEVERE PAIN AFTER FAILURE OF TYPICAL MEDICAL APPROACHES.

THERE ARE OVER 300 TESTIMONIALS ON HIS YOUTUBE CHANNEL:

https://www.youtube.com/@thinkbetterlife-orofacialp9625/videos

WWW.THINKBETTERLIFE.COM

WWW.SPHENOPALATINEGANGLIONBLOCKS.COM

DR IRA L SHAPIRA IS KNOWN THE LEADING PRACTIONER TEACHING SELF-ADMINISTATION OF SPG BLOCKS

GOOGLE "WHO TEACHES SELF ADMINISTRATION OF SPG BLOCKS"

GOOGLE RESULT AI Overview

Dr. Ira Shapira, a neuromuscular dentist in Highland Park, Illinois, is known for teaching patients how to self-administer Sphenopalatine Ganglion (SPG) blocks. He trains both patients and dentists in this technique. Dr. Shapira's website, I Hate Headaches, and his practice, Think Better Life, are resources for learning more about SPG blocks and self-administration.

Galcanezumab reduces trigeminal nociception and is effective in preclinical models of migraine and trigeminal autonomic cephalalgia

Abstract

Objectives/background: This study was undertaken to assess the therapeutic efficacy of galcanezumab in preclinical models of migraine and cluster headache and to determine potential shared trigeminovascular mechanisms of action. Galcanezumab is a humanized monoclonal antibody that binds to the neuropeptide calcitonin gene-related peptide, preventing its biological activity. It has been approved as a preventive treatment for both episodic and chronic migraine and episodic cluster headache, the most common trigeminal autonomic cephalalgia.

Methods: Trigeminovascular and trigeminal-autonomic reflex activation was evoked via electrical stimulation of the dura mater or superior salivatory nucleus (SSN), respectively. Evoked responses were recorded in the spinal trigeminal nucleus along with ongoing spontaneous neuronal and cutaneous noxious-evoked and non-noxious-evoked neuronal activity. Rats received either galcanezumab or human control IgG, and responses were compared between groups.

Results: Galcanezumab robustly reduced spontaneous (maximum decrease in dural-evoked: 73% [±3.5] at 4 h 30 min [p = 0.002]; in SSN-evoked: 67% [±10.7] at 4 h [p = 0.01]) and cutaneous non-noxious-evoked (maximum decrease in dural-evoked: 50% [±5.7], p = 0.004; in SSN-evoked: 47% [±10.5], p = 0.005, at the last recording time point) neuronal activation in the trigeminocervical complex, highlighting a general inhibition of trigeminal sensory processing. Furthermore, it significantly inhibited cutaneous noxious-evoked (maximum decrease in dural-evoked: 38% [±5.2], p = 0.005; in SSN-evoked: 34% [±7.6], p = 0.005, at the last recording time point), durovascular-evoked (maximum decrease 48% [±6] at the last recording time point, p = 0.001), and SSN-evoked responses (maximum decrease: 32% [±2.6] at 4 h, p < 0.001), demonstrating a clear reduction of trigeminal nociception, independent of the mode of activation. Galcanezumab did not have any effect on the mean arterial blood pressure.

Conclusion: Galcanezumab likely acts via a shared trigeminovascular mechanism to dampen noxious and nonnoxious sensory stimuli in preclinical models of migraine and trigeminal autonomic cephalalgias. This further supports the clinical efficacy of galcanezumab for migraine and cluster headache, while demonstrating general inhibition that may be of relevance to other facial pain conditions.

Keywords: cluster headache; galcanezumab; migraine; trigeminal nociceptive processing; trigeminovascular system.

BLOCKING TRIGEMINAL NOCICEPTION TO PREVENT MIGRAINE AND TRIGEMINAL AUTONOMIC CEPHALGIAS

Neuromuscular Dentist in Chicago, IL Accepting Patients Nationwide & Worldwide

Abstract